NuCana (NCNA) Total Non-Current Liabilities (2017 - 2025)

NuCana (NCNA) reported Total Non-Current Liabilities of $949738.7 for Q4 2025, up 380.49% on a YoY basis from $197659.3 in Q4 2024, and up 496.48% sequentially from $159224.7 in Q3 2025.

NuCana (NCNA) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends

NuCana (NCNA) has 9 years of Total Non-Current Liabilities data on file, last reported at $949738.7 in Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 380.49% year-over-year to $949738.7; the trailing twelve-month figure through Dec 2025 stood at $949738.7 (up 380.49% YoY), and the FY2025 full-year result was $941416.4, up 378.23% from the prior year.
  • Total Non-Current Liabilities improved to $949738.7 in Q4 2025, from $159224.7 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $949738.7 in Q4 2025 to a low of $159224.7 in Q3 2025.
  • A 5-year average of $352188.9 and a median of $299782.4 in 2023 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities tumbled 48.09% in 2021 and surged 380.49% in 2025, its largest moves.
  • Tracing NCNA's Total Non-Current Liabilities over 5 years: stood at $283082.2 in 2021, then surged by 83.14% to $518434.3 in 2022, then sank by 40.63% to $307805.7 in 2023, then tumbled by 35.78% to $197659.3 in 2024, then surged by 380.49% to $949738.7 in 2025.
  • Business Quant data shows NCNA's Total Non-Current Liabilities at $949738.7 in Q4 2025, $159224.7 in Q3 2025, and $182764.3 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 4.05 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 949,738.67
Sep 30, 2025 159,224.73
Jun 30, 2025 182,764.26
Mar 31, 2025 171,292.07
Dec 31, 2024 197,659.28
Sep 30, 2024 213,085.23
Jun 30, 2024 267,590.80
Mar 31, 2024 291,759.18
Dec 31, 2023 307,805.67
Sep 30, 2023 354,671.74
Jun 30, 2023 421,709.38
Mar 31, 2023 481,341.77
Dec 31, 2022 518,434.32
Sep 30, 2022 595,166.89
Jun 30, 2022 206,527.53
Mar 31, 2022 250,923.28
Dec 31, 2021 283,082.23
Sep 30, 2021 332,238.59
Jun 30, 2021 387,170.73
Mar 31, 2021 471,590.91